Literature DB >> 11163231

Mechanism of measles virus-induced suppression of inflammatory immune responses.

J C Marie1, J Kehren, M C Trescol-Biémont, A Evlashev, H Valentin, T Walzer, R Tedone, B Loveland, J F Nicolas, C Rabourdin-Combe, B Horvat.   

Abstract

Measles virus (MV) causes profound immunosuppression, resulting in high infant mortality. The mechanisms are poorly understood, largely due to the lack of a suitable animal model. Here, we report that particular MV proteins, in the absence of MV replication, could generate a systemic immunosuppression in mice through two pathways: (1) via MV-nucleoprotein and its receptor FcgammaR on dendritic cells; and (2) via virus envelope glycoproteins and the MV-hemagglutinin cellular receptor, CD46. The effects comprise reduced hypersensitivity responses associated with impaired function of dendritic cells, decreased production of IL-12, and the loss of antigen-specific T cell proliferation. These results introduce a novel model for testing the immunosuppressive potential of anti-measles vaccines and reveal a specific mechanism of MV-induced modulation of inflammatory reactions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11163231     DOI: 10.1016/s1074-7613(01)00090-5

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  38 in total

1.  Selectively receptor-blind measles viruses: Identification of residues necessary for SLAM- or CD46-induced fusion and their localization on a new hemagglutinin structural model.

Authors:  Sompong Vongpunsawad; Numan Oezgun; Werner Braun; Roberto Cattaneo
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

2.  Susceptibility of immature and mature Langerhans cell-type dendritic cells to infection and immunomodulation by human cytomegalovirus.

Authors:  Laura Hertel; Vashti G Lacaille; Herbert Strobl; Elizabeth D Mellins; Edward S Mocarski
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

3.  Measles virus (MV) nucleoprotein binds to a novel cell surface receptor distinct from FcgammaRII via its C-terminal domain: role in MV-induced immunosuppression.

Authors:  David Laine; Marie-Claude Trescol-Biémont; Sonia Longhi; Geneviève Libeau; Julien C Marie; Pierre-Olivier Vidalain; Olga Azocar; Adama Diallo; Bruno Canard; Chantal Rabourdin-Combe; Hélène Valentin
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

4.  Regulatory T cells and Atherosclerosis.

Authors:  Jahaira Lopez Pastrana; Xiaojin Sha; Anthony Virtue; Jietang Mai; Ramon Cueto; In Ae Lee; Hong Wang; Xiao-Feng Yang
Journal:  J Clin Exp Cardiolog       Date:  2012-10-08

5.  Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons.

Authors:  Shaoheng Ni; Kathrin Bernt; Anuj Gaggar; Zong-Yi Li; Hans-Peter Kiem; André Lieber
Journal:  Hum Gene Ther       Date:  2005-06       Impact factor: 5.695

Review 6.  Viral modulation of T-cell receptor signaling.

Authors:  Keith R Jerome
Journal:  J Virol       Date:  2008-02-20       Impact factor: 5.103

7.  Recognition of the measles virus nucleocapsid as a mechanism of IRF-3 activation.

Authors:  Benjamin R tenOever; Marc J Servant; Nathalie Grandvaux; Rongtuan Lin; John Hiscott
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

8.  In vitro suppression of human immunodeficiency virus type 1 replication by measles virus.

Authors:  Mayra García; Xiao-Fang Yu; Diane E Griffin; William J Moss
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

9.  Immunoglobulin g antibody-mediated enhancement of measles virus infection can bypass the protective antiviral immune response.

Authors:  Ianko D Iankov; Manoj Pandey; Mary Harvey; Guy E Griesmann; Mark J Federspiel; Stephen J Russell
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

10.  Measles virus interacts with human SLAM receptor on dendritic cells to cause immunosuppression.

Authors:  Bumsuk Hahm; Nathalie Arbour; Michael B A Oldstone
Journal:  Virology       Date:  2004-06-01       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.